

-

[]

• •

2015 .

:

/

,

,

,

EMBASE MEDLINE.

5 .

,

(.1).

1.

1			

1		,	,
1	,	,	,
2		,	,
2	,	,	,
2	,	,	;

•
•

- ;

.

2015

() ,

() -

,
 -
 ;
 ,
 (10 ())
 ())
 .

-10

30.3 – - []

(Paediatric Rheumatology European Society -
 PReS) (European League against
 Rheumatism - EULAR) 2006 .
 [Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty
 RE, Prieur AM, Ravelli A, Woo P. EULAR/PReS endorsed consensus criteria for the
 classification of childhood vasculitides. Ann Rheum Dis. 2006 Jul;65(7):936-41. Epub 2005 Dec
 1.].

- - II.**
 -
 -
 -
-

- III.**
-
-
-
-
-
-

- IV.**
-
-
-
-
-
-
-

.Kawasaki 1967 . ; ,
 ,
 2002 . 218,6 100 . 137,7 100 .
 2008 [Nakamura

Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010;20:302-7.] , - 9 - 19 100 .

[http://www.cdc.gov/kawasaki/], 3,6 100 . 8,1

100 .

90-95%

5 .

10 , 85-90 %

9-11 .

[1].
2005

2009

100 .

5 ,

2,7

100 .

0-17

6,6

[

2011; .90; 5:49-53].

-
- 5 ,

6

. [Onouchi Y.

Susceptibility genes for Kawasaki disease. *Nihon Rinsho*. Sep 2014;72(9):1554-60]

«

» - 5

40°

10

()

25-100 1

).

(11-30),

(15-20 10^9 /)
 2- (1000 10^9 /),
 (),
 6-8
 (): 2-
 (3 /),
 3-8-
 198 , 44% , 26%,
 18%, 28%, 19%, - 15%.
 - 61% , 5%
 - 35% [11].
 . [12, 13]. 0,16% -
 0,09% - [Guidelines for Diagnosis and Management of Cardiovascular
 Sequelae in Kawasaki Disease (JCS 2013) Digest version. JCS Joint Working Group Circ J.
 2014;78(10):2521-62].

2-3

PR,
ST.

():

QRS,

T,

[7, EULAR/PreS,

2006]:

1. 40 ° 5
2. ; « » /
3. ()
4. 14-21-
5. (50%), 1,5
6. ; -

[Ritei

Uehara, Yosikazu Nakamura, Hirochi Yanagawa Epidemiology of Kawasaki disease in Japan
JMAJ 2005 48(4):183-193]:

1. - : (PR/QT (Q ,), QRS, (ST T- ,), ()
2. - : , , ,
3. : , 2-
4. :
5. : -

6. : , ,
7. : , :
8. : , ,
 , ,
 , « » ,
[8]. , 4 , 2-3,
20% . ,
 .
 , [9].
() -
(, , , ,
) .
() (20-30) ,
 ;
 , 2 /
[10].
 .
 , , 2 5. ,

(American Heart Association AHA)
(American Academy of Pediatrics (AAP))

:

-

() ()

3 / 40 /)
15,000/

(10) 450,000/ 7
>50 /
3 /

(/ -) -
(*Streptococcus pyogenes*) (),
(), , .

», , «
, - ,
, , 5 /
, - 10-15%

5 , ,
« 5 ».
(- *Mycoplasma pneumoniae*)

:

(2) ,

「 」 [14].
 (: *BO1AC06*)
 ()
 (2C). () ()
 80-100 / / 4
)
 48-72 (3-5 / /)
 6-8 ,
 <8 ?
 6) . 8 / ()
 ?) 2-5 / (, *BO1AA03*,
)
 (1A).
 (8-36) 2 / (2B)
 12 48-72
 6- - 2-
 10
 48 2 -
 [15].

- 2 /
- + 80-100 / /

[Taniuchi S, Masuda M, Teraguchi M, Ikemoto Y, Komiyama Y, Takahashi H, et al. Polymorphism of Fc gamma RIIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. *J Clin Immunol.* Jul 2005;25(4):309-13].

(16,6%) [Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. JCS Joint Working Group. *Circ J.*2014;78(10):2521-62.]

:

(8-10 /)
« » :
() 300,000/ 3
133 /

(1B),

()
(2-) (2).
30 / 40 1
H02AB04) 600 / 2 .
H02AB06) 6 2 / / 3 ((

[16].

(-)¹.

[16, 17].

[18, 19].

A.

(4)
5 :
, 1,5 .
- *аневризмы среднего размера*: аневризмы с внутренним диаметром от >4 мм до <8 мм
5 :
1,5-4 8
5 :
, 4

1

off label –

()

B.

-

5-

-

:

I.

:

,

,

;

II.

:

30

;

,

,

,

III.

:

,

,

30

,

,

,

V;

IV.

:

-

,

V;

V.

:

,

(a)

/

,

(b)

/

,

:

-

,

,

,

-

.

.

,

,

,

-

6

.

.

6

„

.

,

,

(

«

»

,

,

. .) [20].

- ; 6-8

- 10-14 ,

;

-

;

- 3-5 / / .

- ,

6-12 .

- , 6 ,

- /

,

,

,

.

[Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. *Circulation* 2004;110:2747–71, Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. JCS Joint Working Group *Circ J*. 2014;78(10):2521-62. Epub 2014 Sep 22,]

				,
I()	,	-	(6-8)	-
II (30 ,60 , 6- ,, 1 5		(.)
		(, -		

)	- . . 30	, - .)		
III ()	1-2 . : . .	3 - - - , 6 - + (). - (- - , -)**	5 / /) (3- ()	.
IV	,			

	<p>· /</p> <p>· , : ·</p> <p>, / · ·</p>	<p>(; - -)</p>	<p>*, Π*</p> <p>(·)</p>	<p>, , , , ·</p>
<p>(V)</p>			<p>· V · - (()) - ·</p>	<p>(D ,). · (D) · ·</p>

·
- ,
- ,
:

- A-
- B-
- C-
- D-
- E-

*- off label -

14

**

-
-
-

T I

[Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. JCS Joint Working GroupCirc J. 2014;78(10):2521-62. Epub 2014 Sep 22]

()	
IV, V	I
I II III	II
- , 12-	
I II III IV, V	I
III IV, V	I
I II	II
III IV, V	I
I II	II
IV, V	I
I II III	II
IV, V	I
I II III	II
IV, V	I
I II III	II
IV, V	I

I II III	II
, -	
IV, V	I
I II III	II
IV, V	I
III	II
I II	III

[Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. JCS Joint Working Group Circ J. 2014;78(10):2521-62. Epub 2014 Sep 22].

I	, / /
II	, / .
III	, / , / .

1.

	30-100 / 4 ; 48-72 . 3-5 / / .
	0,05-0,12 / (-0,05-0,035 /) (1,6-2,5)
/	50 / . -20 ./ (: 60- 85 .- 1,5-2)
/	<1 : -3 / / ., 2 12 -1,5 / / . >1 : -2 / / . 2 12 -1 / / .
	1 / /

2.

- :
 - 12) ()
 - : ; /
 - () , ;
 . (/ , - , ()).

1)

-):
 - (2 3)
 -
 -

2)

- :
 - : , , ,
 . ,
 - , . . .
 - , ,
 . , . ,
 , , .

1-2 .

3)

- :
 - , , .
 ,

[Kawasaki syndrome. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.413; Linnemann CC Jr, Shea L, Partin JC, et al. Reye's syndrome: epidemiologic and viral studies, 1963-1974. Am J Epidemiol 1975; 101:517.](2C). [Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. JCS Joint Working Group. Circ J.2014;78(10):2521-62. Epub 2014 Sep 22].

1. (). 2008. 140 .
2. Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. *BMJ* 2002;342:1424-5
3. Rowley AH, Baker SC, Shulman ST, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. *J Infect Dis* 2011;**203**:1021-30.
4. Burgner D, Davila S, Breunis WB, et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. *PLoS Genet* 2009;**5**:e1000319.
5. Khor CC, Davila S, Shimizu C, et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. *J Med Genet* 2011.
6. Mamtani M, Matsubara T, Shimizu C, et al. Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children. *PLoS ONE* 2010; **5**:e11458.
7. American Heart Association, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. Diagnostic guidelines for Kawasaki disease. *Am J Dis Child* 1990; 144:1218-9
8. Rowley AH, Gonzalez CF, Giding SS, et al. Incomplete Kawasaki disease with coronary artery involvement. *J Pediatr* 1987;110 :409-13
9. Papadodima SA; Sakelliadis EI; Goutas ND; et al. Atypical kawasaki disease presenting with symptoms from the genitourinary system: an autopsy report. [J. Trop Pediatr. 2009; 55\(1\):55-7](#)
10. Sasaki T(1), Miyata R, Hatai Y. et al. Hounsfield unit values of retropharyngeal abscess-like lesions seen in Kawasaki disease. *Acta Otolaryngol.* 2014;134(4):437-40.
11. Baker A.L.; Lu M.; Minich L .L. et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. [J Pediatr. 2009; 154\(4\):592-595](#)
12. Valentini P; Ausili E; Schiavino A et al. Acute cholestasis: atypical onset of Kawasaki disease. [Dig Liver Dis. 2008; 40\(7\):582-4](#)
13. Zulian F; Falcini F; Zancan L. et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. [J Pediatr. 2003; 142\(6\):731-5](#)
14. Newburger J.W., Takahashi M., Gerber M.A. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics* 2004;114: 1708-1733.
15. Ogata S.. Bando Y., Kimura S. et al. The strategy of additional immune globulin and steroid pulse therapy. *J. Cardiol.* 2009; 53: 15-19.
16. Burns JC, Best BM, Mejias A, et al. [Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.](#) *J Pediatr.* 2008;153(6):833-8.
17. Accomando S, Liotta A, Maggio MC et al. [Infliximab administration effective in the treatment of refractory Kawasaki disease.](#) *Pediatr Allergy Immunol.* 2010; 21(7):1091
18. Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for kawasaki disease refractory to initial and additional intravenous immunoglobulin. *Pediatr Infect Dis J* 2011; 30(10):871-6.
19. Tremoulet AH, Pancoast P, Franco A, et al. [Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease.](#) *J Pediatr.* 2012 Sep;161(3):506-512
20. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. JCS Joint Working Group *Circ J.* 2014;78(10):2521-62. Epub 2014 Sep 22.